A Multicenter Open-label Extension Study For Subjects Who Participated In Study B0151003 (Andante Ii)
A Multicenter Open-label Extension Study For Subjects Who Participated In Study B0151003 (Andante Ii)
This is a multi-center Phase 2, open label, safety extension study in subjects with moderate to severe CD who are anti-TNF inadequate responders. Subjects eligible for this study will have completed the 12-week induction period of study B0151003 and will be enrolled as either responders or non responders.
Inclusion Criteria:
Exclusion Criteria:
New York, New York 10065, United States
New York, New York 10065, United States
Richmond, Virginia 23298, United States
Curitiba, Paraná 80810-040, Brazil
Hilleroed, 3400, Denmark
Koebenhavn NV, 2400, Denmark
Koege, 4600, Denmark
Szeged, 6720, Hungary
Dublin, D04 T6F4, Ireland
Dublin, D07 K201, Ireland
Beith Vagan, Jerusalem 91031, Israel
Jerusalem, 91120, Israel